US20170151289A1 - Formulations and methods for treatment of wounds and inflammatory skin conditions - Google Patents
Formulations and methods for treatment of wounds and inflammatory skin conditions Download PDFInfo
- Publication number
- US20170151289A1 US20170151289A1 US15/431,107 US201715431107A US2017151289A1 US 20170151289 A1 US20170151289 A1 US 20170151289A1 US 201715431107 A US201715431107 A US 201715431107A US 2017151289 A1 US2017151289 A1 US 2017151289A1
- Authority
- US
- United States
- Prior art keywords
- emu oil
- weight
- cream
- skin
- cetirizine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 208000027418 Wounds and injury Diseases 0.000 title abstract description 35
- 206010052428 Wound Diseases 0.000 title abstract description 34
- 238000000034 method Methods 0.000 title abstract description 30
- 238000011282 treatment Methods 0.000 title abstract description 23
- 238000009472 formulation Methods 0.000 title description 21
- 230000002757 inflammatory effect Effects 0.000 title description 13
- 239000010776 emu oil Substances 0.000 claims abstract description 88
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 66
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 66
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 61
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims abstract description 52
- 230000001387 anti-histamine Effects 0.000 claims abstract description 52
- 230000001624 sedative effect Effects 0.000 claims abstract description 44
- 229960003624 creatine Drugs 0.000 claims abstract description 33
- 239000006046 creatine Substances 0.000 claims abstract description 33
- 229940109239 creatinine Drugs 0.000 claims abstract description 33
- 239000002253 acid Substances 0.000 claims abstract description 26
- 150000001408 amides Chemical class 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 51
- 229960001803 cetirizine Drugs 0.000 claims description 50
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 claims description 27
- 229960001508 levocetirizine Drugs 0.000 claims description 27
- 239000003755 preservative agent Substances 0.000 claims description 11
- 230000002335 preservative effect Effects 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 abstract description 31
- 230000002195 synergetic effect Effects 0.000 abstract description 13
- 230000004968 inflammatory condition Effects 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 206010072170 Skin wound Diseases 0.000 abstract description 8
- 241000124008 Mammalia Species 0.000 abstract description 5
- 239000006071 cream Substances 0.000 description 46
- 210000003491 skin Anatomy 0.000 description 45
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 230000029663 wound healing Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 230000035876 healing Effects 0.000 description 20
- 230000003110 anti-inflammatory effect Effects 0.000 description 15
- 230000009286 beneficial effect Effects 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 12
- 201000004681 Psoriasis Diseases 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 230000000996 additive effect Effects 0.000 description 10
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 10
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 10
- 206010012438 Dermatitis atopic Diseases 0.000 description 9
- 229960003792 acrivastine Drugs 0.000 description 9
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 9
- 229940125715 antihistaminic agent Drugs 0.000 description 9
- 201000008937 atopic dermatitis Diseases 0.000 description 9
- 229960004314 bilastine Drugs 0.000 description 9
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 description 9
- 229960001971 ebastine Drugs 0.000 description 9
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 9
- 229960003592 fexofenadine Drugs 0.000 description 9
- 229960003088 loratadine Drugs 0.000 description 9
- 229960005328 rupatadine Drugs 0.000 description 9
- WUZYKBABMWJHDL-UHFFFAOYSA-N rupatadine Chemical compound CC1=CN=CC(CN2CCC(CC2)=C2C3=NC=CC=C3CCC3=CC(Cl)=CC=C32)=C1 WUZYKBABMWJHDL-UHFFFAOYSA-N 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 208000003251 Pruritus Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000035515 penetration Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000001804 emulsifying effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 6
- 229960002216 methylparaben Drugs 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000001139 anti-pruritic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008238 biochemical pathway Effects 0.000 description 4
- 239000000938 histamine H1 antagonist Substances 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 102000000543 Histamine Receptors Human genes 0.000 description 3
- 108010002059 Histamine Receptors Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000006748 scratching Methods 0.000 description 3
- 230000002393 scratching effect Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000003631 expected effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229940048921 humira Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001823 pruritic effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000323792 Emus Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010048649 Koebner phenomenon Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010038001 Rebound effect Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 229940008201 allegra Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229940020485 elidel Drugs 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940049337 neosporin Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- -1 oleic acid Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108010046630 polymyxin B drug combination bacitracin Proteins 0.000 description 1
- 229940103255 polysporin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940112971 protopic Drugs 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 229940072291 soriatane Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940071598 stelara Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229940036139 zyrtec Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Definitions
- the emu ( Dromiceius novae - hollandiae ) is the second largest member of the group of flightless birds and is indigenous to Australia. Emus can be raised like ordinary farm animals and used for their valuable products, which include very low fat meat, supple leather hides, decorative and nutritional eggs, and rich oil. Emu oil may be extracted or rendered from the body fat of the emu and is known to contain triglyceride esters of long-chain saturated and unsaturated fatty acids, including oleic acid, linoleic acid, palmitic acid, and stearic acid.
- Atopic dermatitis and other forms of eczema are inflammatory, pruritic (i.e., itchy) skin diseases that affect between 10 and 20 percent of the United States (U.S.) population, causing considerable morbidity, poor quality of life, and high medical costs for both the patient and society.
- Topically administered glucocorticoids are a main form of therapy; however, prolonged use of topical glucocorticoids is associated with skin thinning, permanent stretch marks, dermal atrophy, rebound effects, tachyphylaxis, and potential systemic absorption, which can cause numerous systemic side effects.
- Topical calcineurin inhibitors e.g., Elidel®. and Protopic® creams and ointments
- Psoriasis is also a chronic pruritic inflammatory skin disease affecting 2% of the U.S. population Inflammation and tumor necrosis factor-alpha (“TNF-alpha”) are of crucial importance in the pathogenesis of psoriasis and its treatment.
- TNF-alpha tumor necrosis factor-alpha
- topical glucocorticoids, and vitamin D analogs either by themselves or in combination with phototherapy or systemic agents (such as methotrexate, cyclosporine A, Humira®, Stelara®, Soriatane®, etc.), have been used for therapy.
- these agents can be extremely expensive, costing more than $20,000 per year per patient.
- Histamine is a compound involved in local immune responses of humans and other animals. As part of an immune response to foreign pathogens, histamine is produced by basophils and mast cells found in nearby connective tissues. Upon release from these cells, histamines produce increased vascular permeability, causing fluid to escape from capillaries into tissues, which can lead to inflammation and itchiness among other responses. Histamine triggers an immune system response by combining with specific cellular histamine receptors. The four histamine receptors that have been discovered in humans and animals are designated H 1 through H 4 . Compounds, known as antihistamines, have been developed that do not prevent the release of histamine but instead inhibit the action of histamine by blocking it from attaching to the histamine receptors.
- H 1 antihistamines Most commonly used antihistamines inhibit action specifically at the H 1 receptor and are referred to as H 1 antihistamines. While some H 1 antihistamines have sedative side effects, so-called “second generation” or “non-sedating” antihistamines do not cross the blood-brain barrier and, thus, do not cause drowsiness. Further, not all H 1 antihistamines inhibit the inflammatory response that results from the release of histamine in humans.
- Pcr phosphocreatine molecule
- ATP adenosine triphosphate
- Topical application of Pcr can “recharge” skin cells.
- Pcr is a very unstable molecule.
- a formulation for the treatment of wounds and inflammatory skin conditions of the skin includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more thereof; a therapeutic amount of creatine; a therapeutic amount of creatinine; and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination thereof.
- the non-sedating antihistamine is selected from the group consisting of cetirizine, levocetirizine, loratadine, fexofenadine, rupatadine, acrivastine, ebastine, bilastine, and a combination of two or more thereof.
- the physiologically acceptable acid of the non-sedating antihistamine is selected from the group consisting of an acid of cetirizine, an acid of levocetirizine, an acid of loratadine, an acid of fexofenadine, an acid of rupatadine, an acid of acrivastine, an acid of ebastine, an acid of bilastine, and a combination of two or more thereof.
- the salt of the non-sedating antihistamine is selected from the group consisting of a salt of cetirizine, a salt of levocetirizine, a salt of loratadine, a salt of fexofenadine, a salt of rupatadine, a salt of acrivastine, a salt of ebastine, a salt of bilastine, and a combination of two or more thereof.
- the amide of a non-sedating antihistamine is selected from the group consisting of an amide of cetirizine, an amide of levocetirizine, an amide of loratadine, an amide of fexofenadine, an amide of rupatadine, an amide of acrivastine, an amide of ebastine, an amide of bilastine, and a combination of two or more thereof.
- the composition includes 0.1 to 5.0 wt.-% of the antihistamine, 0.2-10.0 wt.-% creatine, 0.1-5.0 wt.-% creatinine, and at least 75 wt.-% of the emu oil product. In at least one embodiment, the composition includes 2.0 wt.-% of the antihistamine, 1.0 wt.-% creatine, 0.5 wt.-% creatinine, and at least 85 wt.-% of the emu oil product. In at least one embodiment, the composition further includes a preservative, and a neutral emulsifying agent. In at least one embodiment, the composition includes 0.1 to 1.0 wt.-% of preservative. In at least one embodiment, the composition includes 0.2 wt.-% of preservative. In at least one embodiment, the preservative is methylparaben, and the emulsifying agent is propylene glycol.
- the antihistamine is selected from the group consisting of cetirizine, a physiologically acceptable acid of cetirizine, a salt of cetirizine, an amide of cetirizine, and a combination of two or more thereof. In at least one embodiment, the antihistamine is selected from the group consisting of levocetirizine, a physiologically acceptable acid of levocetirizine, a salt of levocetirizine, an amide of levocetirizine, and a combination of two or more thereof.
- a method of treating wounds and inflammatory conditions of the skin in mammals includes topically applying to the skin of a mammal a topically administrable composition that includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more thereof, a therapeutic amount of creatine, a therapeutic amount of creatinine, and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination thereof; and repeating the topical application of the composition as indicated for resolution or control of the skin wound.
- a topically administrable composition that includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating anti
- the method includes a non-sedating antihistamine is selected from the group consisting of cetirizine, levocetirizine, loratadine, fexofenadine, rupatadine, acrivastine, ebastine, bilastine, and a combination of two or more thereof.
- the method includes a physiologically acceptable acid of the non-sedating antihistamine is selected from the group consisting of an acid of cetirizine, an acid of levocetirizine, an acid of loratadine, an acid of fexofenadine, an acid of rupatadine, an acid of acrivastine, an acid of ebastine, an acid of bilastine, and a combination of two or more thereof.
- the method includes a salt of the non-sedating antihistamine is selected from the group consisting of a salt of cetirizine, a salt of levocetirizine, a salt of loratadine, a salt of fexofenadine, a salt of rupatadine, a salt of acrivastine, a salt of ebastine, a salt of bilastine, and a combination of two or more thereof.
- the method includes an amide of a non-sedating antihistamine is selected from the group consisting of an amide of cetirizine, an amide of levocetirizine, an amide of loratadine, an amide of fexofenadine, an amide of rupatadine, an amide of acrivastine, an amide of ebastine, an amide of bilastine, and a combination of two or more thereof.
- the composition of the method includes 0.1 to 5.0 wt.-% of the antihistamine, 0.2-10.0 wt.-% creatine, 0.1-5.0 wt.-% creatinine, and at least 75 wt.-% of the emu oil product. In at least one embodiment, the composition of the method includes 2.0 wt.-% of the antihistamine, 1.0 wt.-% creatine, 0.5 wt.-% creatinine, and at least 85 wt.-% of the emu oil product.
- the composition of the method includes an antihistamine selected from the group consisting of cetirizine, a physiologically acceptable acid of cetirizine, a salt of cetirizine, an amide of cetirizine, and a combination of two or more thereof. In at least one embodiment, the composition of the method includes an antihistamine selected from the group consisting of levocetirizine, a physiologically acceptable acid of levocetirizine, a salt of levocetirizine, an amide of levocetirizine, and a combination of two or more thereof.
- FIG. 1 shows a method of treating wounds of the skin according to the present disclosure.
- the present application discloses various formulations and methods for using the same for the treatment of wounds and inflammatory conditions of the skin in mammals. According to one aspect of the present disclosure, a formulation for the treatment and promotion of healing of wounds of the skin is disclosed.
- a formulation for the treatment and promotion of healing of wounds of the skin is disclosed.
- emu oil refers to lipid compositions, oils, and preparations of oils derived from the emu.
- Emu oil extracted or rendered from the body fat of the emu bird, has a number of beneficial properties for the treatment of wounds and inflammatory conditions of the skin.
- the beneficial properties of emu oil include that emu oil is noncomedogenic, antibacterial, moisturizing, anti-inflammatory, emulsifying, enhances transdermal penetration, and has a low potential for skin irritation. Taking each of these beneficial properties in turn, emu oil is noncomedogenic, meaning emu oil will not clog skin pores. Other such oils tend to clog pores in skin, which can result in the development of acne.
- Such oils include synthetic oils, like mineral oils, or animal oils, like mink or lard.
- moisturizers by themselves are therapeutic agents in the treatment of patients with psoriasis, atopic dermatitis, and other forms of eczema because moisturizers can improve skin hydration and normalize keratinocyte differentiation.
- Emu oil has excellent skin barrier penetrating features and can enhance the transdermal penetration of active compounds, compounds otherwise unable to effectively treat disease beyond the epidermis.
- Emu oil is known to contain triglyceride esters of long-chain saturated and unsaturated fatty acids, including oleic acid, linoleic acid, palmitic acid, and stearic acid.
- Table 1 contains the typical chemical composition of emu oil which, being almost entirely triglyceride in nature, is a nearly completely neutral lipid.
- the transdermal penetration properties of emu oil are generally attributable to oleic acid, which enables penetration by fluidizing the intercellular lipids of the stratum corneum.
- studies of various long-chain fatty acids, including oleic acid, used as penetration enhancers have not reported a synergistic effect of using this particular property of emu oil with other active compounds as described herein.
- emu oil Two other valuable properties of emu oil for a topical treatment delivery system are its emulsifying properties and low potential for irritation. Such emulsifying properties, absent the potential for irritation, enable emu oil to serve as both a carrier and an active compound in a formulation.
- emu oil has anti-inflammatory properties.
- topically administered emu oil has been shown to be as effective as orally administered, high-dose ibuprofen. Research suggests that at least some of emu oil's anti-inflammatory properties are due to TNF-alpha inhibition, which is a key target inflammatory molecule in systemic psoriasis therapy.
- Examples of prescription treatments for systemic psoriasis that operate by inhibiting TNF-alpha include Enbrel® and Humira®.
- Enbrel® and Humira® examples of prescription treatments for systemic psoriasis that operate by inhibiting TNF-alpha.
- emu oil may act as a therapeutic agent for some skin conditions independent of any other active compound.
- emu oil may be included in a formulation to dissolve one or more additional active compounds, carry the one or more additional active compounds through the skin barrier, and provide one or more therapeutic effects that are synergistically enhanced by the combination with the one or more additional active compounds.
- emu oil may be combined with a non-sedating antihistamine compound to treat wounds and inflammatory conditions of the skin such as psoriasis and atopic dermatitis.
- a non-sedating antihistamine is cetirizine.
- Cetirizine is commonly used orally to treat hay fever, urticaria (i.e., hives), angioedema, and allergies.
- cetirizine has numerous pharmacological effects that are highly useful for the treatment of wounds and inflammatory conditions of the skin if used as a topical agent.
- cetirizine As a potent second-generation antihistamine, cetirizine has antipruritic properties that are very beneficial in treating wounds and inflammatory skin conditions, particularly atopic dermatitis, which has been described as a vicious cycle of itch-scratch-itch. In addition to relieving the symptoms of itch, antipruritic antihistamines help to prevent progression of the condition by suppressing the scratching impulse (i.e., the so-called Koebner phenomenon). Moreover, as a second-generation, non-sedating antihistamine, cetirizine has an excellent safety profile, which enables cetirizine (marketed as Zyrtec®) to be sold over-the-counter without a prescription.
- cetirizine and its related isomers are unique among non-sedating antihistamines in that each has various anti-inflammatory properties useful for the treatment of inflammatory skin disease. Namely, cetirizine inhibits expression of adhesion molecules in patients with both atopic dermatitis and psoriasis and inhibits both T lymphocytes and monocytes, which play a central role in the pathogenesis of atopic dermatitis and psoriasis. Finally, cetirizine exerts anti-inflammatory effects on neutrophils apart from H 1 antagonism and inhibits eosinophil-related skin inflammation.
- cetirizine The anti-inflammatory properties of cetirizine are distinct from its other H 1 antihistamine features.
- diphenhydramine (marketed as Benadryl®) is specifically contraindicated to treat inflammatory skin disease, such as eczema and psoriasis.
- the packaging for diphenhydramine includes a warning label clearly stating that it should not be used on “raw or broken skin” or “areas producing discharge.”
- Other commonly used non-sedating antihistamines that do not have anti-inflammatory properties include loratadine (marketed as Claritin®) and fexofenadine (marketed as Allegra®). Therefore, not all non-sedating, H 1 antihistamines are appropriate for the treatment of inflammatory skin conditions.
- emu oil and cetirizine both have anti-inflammatory properties, each utilizes completely different biochemical pathways. Consequently, instead of enabling merely additive beneficial anti-inflammatory effects, the combination of emu oil and cetirizine provides a synergistic enhancement of the beneficial effects of both active compounds in treating inflammatory skin conditions. Furthermore, emu oil, in addition to being a therapeutic agent, also enables penetration of cetirizine into the skin, thereby improving the efficacy of cetirizine separate from the synergistic effect.
- Cetirizine is a racemic 50/50 mixture of levocetirizine, which is the active enantiomer (or L-stereoisomer), and the much less biologically active enantiomer (or D-stereoisomer)
- levocetirizine is a non-sedating antihistamine that includes anti-inflammatory properties.
- emu oil may be combined with levocetirizine to treat wounds and inflammatory conditions of the skin such as psoriasis and atopic dermatitis.
- Other non-sedating, anti-inflammatory antihistamines include, but are not limited to rupatadine, acrivastine, ebastine and bilastine.
- Wound healing after any type of injury to the skin is an extremely complex, multistage process characterized by inflammation and new tissue formation and remodeling, which are both processes that require great amounts of cellular energy. Excessive inflammation and bacterial infection can delay wound healing and cause further scaring. Moreover, serious skin infections can become systemic and life threatening, for example, as with sepsis. Many wound healing creams, such as Neosporin® or Polysporin®, contain antibacterial medicines. However, dermatologists prescribe these wound healing creams infrequently because of high prevalence of contact dermatitis, or “poison ivy-type” allergic reactions, associated with the use of such treatments. Further, most healing wounds show signs of pruritus, and the resulting scratching can delay wound healing.
- emu oil may be combined with a mixture of creatine and creatinine, denoted as “Cr/Crt,” to treat and promote the healing of wounds of the skin, as well as inflammatory skin conditions such as psoriasis and atopic dermatitis.
- Cr/Crt a mixture of creatine and creatinine
- the application of Cr/Crt results in the regeneration of phosphocreatine molecules (“Pcr”) in mammalian skin.
- Pcr phosphocreatine molecules
- topical application of Pcr via the application of Cr/Crt can provide skin cells with the energy needed to heal wounds.
- the epidermal transport properties of emu oil facilitate penetration of Cr/Crt through the skin barrier, which is particularly effective in treating partially healed wounds.
- emu oil and Cr/Crt in one topical formulation enables these active compounds to synergistically aid the healing of wounds and inflammatory conditions of the skin.
- emu oil also promotes wound healing by reducing excessive inflammation, which can interfere with wound healing and induce excessive scaring of a wound.
- the antibacterial properties of emu oil promote wound healing by reducing the incidence of secondary infection, which can further interfere with the healing process.
- Previous studies have shown that emu oil alone can decrease wound healing time and decrease scar formation in burn victims based on the results of a double-blind study. Therefore, by combining emu oil and Cr/Crt in one treatment, the formulation may promote and facilitate the healing process of skin wounds by providing cellular energy to drive the healing process while concurrently reducing inflammation and the incidence of bacterial infection.
- emu oil may be combined with Cr/Crt and a non-sedating antihistamine to treat skin wounds and promote the healing process of skin wounds, as well as inflammatory skin conditions.
- non-sedating antihistamines such as cetirizine
- cetirizine have anti-inflammatory and antipruritic properties that operate through different biochemical pathways from emu oil. These properties can be advantageous in promoting the healing process of skin wounds. Most healing skin wounds show signs of pruritus, and the resulting scratching can delay wound healing. Accordingly, the antipruritic properties of cetirizine are of value in the healing process.
- non-sedating antihistamines such as cetirizine
- cetirizine can promote wound healing by reducing excessive inflammation that can interfere with wound healing and induce excessive scaring of a wound.
- the combination of a non-sedating antihistamine, Cr/Crt, and emu oil has now been shown to synergistically potentiate the effects of these active compounds to accelerate the wound healing process. Consequently, a formulation combining emu oil, Cr/Crt, and a non-sedating antihistamine has been demonstrated to facilitate the wound healing process by addressing key aspects of the healing process via different biochemical pathways.
- the use of natural energy supplementation, for example with the topical use of Cr/Crt, in combination with anti-inflammatory compounds to facilitate the healing process in mammalian skin has not been disclosed previously.
- a formulation 10 may contain by weight 75-100% emu oil, 0.1-5.0% non-sedating antihistamine, a Cr/Crt mixture of 0.2-10.0% creatine and 0.1-5.0% creatinine, and 0.1-1.0% preservative, with the balance being a neutral emulsifying solvent.
- the formulation 10 may contain by weight 75-100% emu oil, 0.1-5.0% cetirizine, a Cr/Crt mixture of 0.2-10.0% creatine and 0.1-5.0% creatinine, 0.1-1.0% methylparaben preservative, and the balance propylene glycol or other neutral emulsifying solvent.
- the formulation 10 may contain by weight at least 85% emu oil, 2.0% cetirizine, a Cr/Crt mixture of 1% creatine and 0.5% creatinine, 0.2% methylparaben preservative, and the balance propylene glycol. In at least one embodiment, the formulation 10 may contain by weight 75-100% emu oil, 0.1-5.0% levocetirizine, a Cr/Crt mixture of 0.2-10.0% creatine and 0.1-5.0% creatinine, 0.1-1.0% methylparaben preservative, and the balance propylene glycol or other neutral emulsifying solvent.
- the formulation 10 may contain by weight at least 85% emu oil, 2.0% levocetirizine, a Cr/Crt mixture of 1% creatine and 0.5% creatinine, 0.2% methylparaben preservative, and the balance propylene glycol.
- the formulations disclosed herein may be used in a method 100 of treating wounds and inflammatory conditions of the skin as shown in FIG. 1 .
- the method 100 may include a step 110 of applying the formulation 10 to an affected area of skin.
- the method 100 may further include a step 120 of periodically repeating application of the formulation 10 to the affected area of skin until the wound is healed or the inflammatory condition is resolved or controlled.
- Cream A included Cr/Crt and cetirizine in an emu oil base
- Cream C included only emu oil
- Cream D included Cr/Crt in an emu oil base
- Cream E included cetirizine in an emu oil base.
- Cream B which contained no active compounds, included only propylene glycol base and served as a placebo.
- Cream B was used as a control preparation to provide a reference point for the degree of improvement observed for the other trial preparations.
- Each cream included an identical amount of Cr/Crt, namely 1.5% by weight, which included 1.0% creatine and 0.5% creatinine by weight. Further, each cream included methylparaben as a preservative and varying amounts of propylene glycol as a neutral emulsifying solvent. The study was conducted for 15 days.
- Subjects selected for the study had at least five different wounds on different areas of their body.
- the causes of the wounds included in the study included skin cancer treatment sites, shave or burn removal of warts, and skin biopsy sites. Accordingly, each research subject applied each of the trial creams to a different wound site on the subject's body selected at random by the subject.
- Each trail cream was applied on one wound only. Consequently, each research subject was his/her own positive and negative control. Further, though each wound was somewhat different and located in different anatomical areas from one another, the random selection of the treatment site by the subject for a given trial cream ensured statistical independence in the design of the study.
- each research subject completed a questionnaire specifically asking “which of the five creams worked the best” and asking the subject to numerically rate the efficacy of each cream on a scale of 0 (not effective) to 10 (extremely effective). The subjects' ratings were then multiplied by a factor of ten to enable simple percentage point comparisons between the trial creams.
- each subject was asked to report any systemic or dermatological side effects of the creams, such as irritation, stinging, or pruritus. The subjects were asked to rank the trial cream that produced the fastest healing with least side effects as a “10.” After the subjects ranked the cream that worked the best, each subject was told that cream B was a placebo and was asked to rate creams C, D, and E in comparison to cream B.
- the clinical response of each subject was assessed by the principal investigator, a physician trained, experienced, and Board Certified in dermatology, at the end of the 15-day study by comparing the condition of the subjects' wounds to a pre-trial evaluation on 0 to 10 scale similar to that at used by the subjects, where “10” indicated the cream that produced the fastest healing with least side effects, “5” indicated that wound healing was 50% better than the placebo, and zero indicted that wound healing was no better than the placebo.
- the physician compared the rate of healing and subjective side effects, such as pain, itching and burning, of creams A, C, D, and E in comparison to the placebo, Cream B.
- the physician's evaluations were then multiplied by a factor of ten to enable simple percentage point comparisons between the trial creams.
- the study coordinator obtained clinical photographs of all areas treated at the beginning and end of the study.
- the research subjects did not use any other prescription medication or over-the-counter topical preparation during the duration of the study. Informed written consent was obtained prior to initiation of the study from each research subject. No financial compensation was provided to any of the research subjects; however, each received a complimentary office visit and free medication. Further, at the end of the study, the subjects were offered and received a free complimentary tube of the cream of their choice (either cream A, B, C, D, or E).
- Table 2 presents the physician's evaluations of the improvement or worsening of the research subjects' skin conditions by the end of the study, relative to the beginning of the study and the control Cream B, for each of the trial creams A, C, D, and E.
- Cream A was rated most effective because it demonstrated the greatest improvement compared to creams B, C, D, and E, as reflected in the mean evaluation ratings across all subjects.
- Statistical analysis determined that the demonstrated improved effect of Cream A over the other creams was statistically significant (i.e., p ⁇ 0.05). Further, Cream A had no reported side effects.
- Table 2 includes a column of data for the “Additive Effect of Creams C, D, and E” calculated for each subject based upon the physician's evaluation.
- the calculated additive effect of Cream C, Cream D, and Cream E was determined by, first, subtracting the rated effect of Cream B (the control) from the ratings given to Cream C, Cream D, and Cream E, which results in a value representing the beneficial effect of each cream in addition to the effect provided by Cream B. The resulting additional effects were then added together.
- the calculated additive effect quantifies the combined effects of Cream C, Cream D, and Cream E, beyond the effect of the control cream, attributable to the active compounds operating separately.
- the calculated additive effect represents the expected or anticipated effect of combining and administering the three active compounds, Cr/Crt, cetirizine, and emu oil.
- the extent to which the rated effect of Cream A exceeds the calculated additive effect of Cream C, Cream D, and Cream E represents the unexpected and synergistic effect of combining and administering the three active compounds together.
- the synergistic effect may be calculated by subtracting the calculated additive effect of Cream C, Cream D, and Cream E from the rated evaluations for Cream A.
- Table 2 further includes the resulting unexpected and synergistic effect for each subject under column heading, “Synergistic Effect of Cream A,” which contains the calculated percentage point improvement of Cream A produced by the synergistic effect of Cream A beyond the simple additive effects of the active compounds administered separately via Cream C, Cream D, and Cream E.
- Cream A was on average 50% more effective than the net effects of Cream C, Cream D, and Cream E taken separately. Further, the synergistic effect was statistically significant. Because the ratings given to Cream A were statistically greater than the calculated additive effect of Cream C, Cream D, and Cream E, one may conclude that the combined effect of the active compounds included in Cream A exceeded the expected effect of these compounds acting separately by 50% on average. Therefore, the study unequivocally demonstrated that Cr/Crt, cetirizine, and emu oil synergistically potentiate each other's beneficial effects and that the synergistic effect was statistically significant.
- Table 3 presents the research subjects' ratings of their own skin conditions at the end of the study, relative to the beginning of the study, for each of the trial creams A, B, C, and D. As shown in Table 3, the subjects' ratings generally corroborated the physician's evaluations. For example, most of the research subjects rated Cream A as the most effective for the treatment of his/her wound to a statistically significant degree. One subject rated Cream D (Cr/Crt and emu oil) as most effective. Unlike Cream A, which demonstrated statistically significant improvement in comparison to the placebo (Cream B), creams C, D, and E did not achieve statistically significant improvement in comparison to Cream B.
- Cream A was demonstrated to be 88% more effective than Cream B (the control) to a statistically significant degree as rated by the research subjects.
- Cream A was on average 24% more effective than the net effects of Cream C, Cream D, and Cream E taken separately, thereby demonstrating the same synergistic effect proven with the physician's evaluations, but as rated by the subjects.
- the synergistic effect based on the subjects' ratings was highly suggestive but not statistically significant (i.e., 0.10>p>0.05).
- the subjects' ratings similarly corroborated the physician's evaluations indicating a statistically significant improvement in wound healing using Cr/Crt in combination with emu oil. None of the research subjects reported any systemic side effects from any of the creams A, B, C, D, or E.
- the disclosure may have presented a method and/or process as a particular sequence of steps.
- the method or process should not be limited to the particular sequence of steps described.
- Other sequences of steps may be possible and are therefore contemplated by the inventor. Therefore, the particular order of the steps disclosed herein should not be construed as limitations of the present disclosure.
- disclosure directed to a method and/or process should not be limited to the performance of their steps in the order written. Such sequences may be varied and still remain within the scope of the present disclosure.
Abstract
The disclosure of the present application includes topically administrable compositions and methods for treating wounds and inflammatory conditions of the skin in mammals. In an exemplary embodiment, the composition includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more of these; a therapeutic amount of creatine; a therapeutic amount of creatinine; and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination of these. The combination of non-sedating antihistamine, creatine, and creatinine with emu oil has been found to produce a synergistic effect that is more effective in the treatment of skin wounds than the compounds used separately.
Description
- This application is related to, claims the priority benefit of, and is a U.S. continuation application of, U.S. patent application Ser. No. 14/394,641, filed Oct. 15, 2014 and issued as U.S. Pat. No. 9,566,306 on Feb. 14, 2017, which is related to, and is a U.S. national phase application of, International Patent Application Serial No. PCT/US13/32728, filed Mar. 17, 2013, which is related to, and claims the priority benefit of, U.S. Provisional Patent Application Ser. No. 61/624,725, filed Apr. 16, 2012, and U.S. Provisional Patent Application Ser. No. 61/725,761, filed Nov. 13, 2012. The contents of each of the aforementioned patent applications are hereby incorporated by reference in their entirety into this disclosure.
- The emu (Dromiceius novae-hollandiae) is the second largest member of the group of flightless birds and is indigenous to Australia. Emus can be raised like ordinary farm animals and used for their valuable products, which include very low fat meat, supple leather hides, decorative and nutritional eggs, and rich oil. Emu oil may be extracted or rendered from the body fat of the emu and is known to contain triglyceride esters of long-chain saturated and unsaturated fatty acids, including oleic acid, linoleic acid, palmitic acid, and stearic acid.
- Atopic dermatitis and other forms of eczema are inflammatory, pruritic (i.e., itchy) skin diseases that affect between 10 and 20 percent of the United States (U.S.) population, causing considerable morbidity, poor quality of life, and high medical costs for both the patient and society. Topically administered glucocorticoids are a main form of therapy; however, prolonged use of topical glucocorticoids is associated with skin thinning, permanent stretch marks, dermal atrophy, rebound effects, tachyphylaxis, and potential systemic absorption, which can cause numerous systemic side effects. Topical calcineurin inhibitors (e.g., Elidel®. and Protopic® creams and ointments) are effective but are infrequently used as a result of FDA-required “black box” warnings concerning a potential increase in systemic malignancies in patients using these topical preparations.
- Psoriasis is also a chronic pruritic inflammatory skin disease affecting 2% of the U.S. population Inflammation and tumor necrosis factor-alpha (“TNF-alpha”) are of crucial importance in the pathogenesis of psoriasis and its treatment. Based on the severity of the disease presentation, topical glucocorticoids, and vitamin D analogs, either by themselves or in combination with phototherapy or systemic agents (such as methotrexate, cyclosporine A, Humira®, Stelara®, Soriatane®, etc.), have been used for therapy. However, these agents can be extremely expensive, costing more than $20,000 per year per patient.
- Histamine is a compound involved in local immune responses of humans and other animals. As part of an immune response to foreign pathogens, histamine is produced by basophils and mast cells found in nearby connective tissues. Upon release from these cells, histamines produce increased vascular permeability, causing fluid to escape from capillaries into tissues, which can lead to inflammation and itchiness among other responses. Histamine triggers an immune system response by combining with specific cellular histamine receptors. The four histamine receptors that have been discovered in humans and animals are designated H1 through H4. Compounds, known as antihistamines, have been developed that do not prevent the release of histamine but instead inhibit the action of histamine by blocking it from attaching to the histamine receptors. Most commonly used antihistamines inhibit action specifically at the H1 receptor and are referred to as H1 antihistamines. While some H1 antihistamines have sedative side effects, so-called “second generation” or “non-sedating” antihistamines do not cross the blood-brain barrier and, thus, do not cause drowsiness. Further, not all H1 antihistamines inhibit the inflammatory response that results from the release of histamine in humans.
- Zemtsov is credited with discovering and confirming the presence of the phosphocreatine molecule (“Pcr”) in human skin. Pcr has been found in both skin and internal organs, like skeletal muscle, and is an important energy storage molecule. Pcr assists in regenerating adenosine triphosphate (“ATP”) molecules during periods of high metabolic demand, or ischemia. In turn, ATP molecules produce the energy required for all cellular functions. Topical application of Pcr can “recharge” skin cells. However, Pcr is a very unstable molecule. Nonetheless, Pcr can be regenerated by skin cells by topically applying a mixture of creatine and creatinine, denoted as “Cr/Crt.” Topical mixtures of Cr/Crt have been used for the treatment and prevention of wrinkles and similar cosmetic applications. However, Cr/Crt has not previously been used in medical applications.
- Extensive investments of time and capital are required to obtain Federal Drug Administration (FDA) approval to sell and market a new drug. The cost of approval is one reason that only three topical dermatological drugs were approved by the FDA in the last five years. Instead, pharmaceutical companies are primarily directing their efforts to develop and patent new delivery systems and formulations to more efficiently carry active ingredients (i.e., drugs) through the stratum corneum skin barrier. These new formulations include solid lipid nanoparticles, liposomes and niosomes, transferosomes, ethosomes, cyclodextrins, and sol-gel microcapsules.
- Accordingly, there is a need for an anti-inflammatory, antipruritic, and moisturizing topical formulation for treating and promoting the healing of wounds and inflammatory conditions of the skin.
- According to one aspect of the present invention, a formulation for the treatment of wounds and inflammatory skin conditions of the skin is disclosed. In at least one embodiment, a topically administrable composition for treating wounds and inflammatory conditions of the skin in mammals includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more thereof; a therapeutic amount of creatine; a therapeutic amount of creatinine; and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination thereof.
- In at least one embodiment, the non-sedating antihistamine is selected from the group consisting of cetirizine, levocetirizine, loratadine, fexofenadine, rupatadine, acrivastine, ebastine, bilastine, and a combination of two or more thereof. The physiologically acceptable acid of the non-sedating antihistamine is selected from the group consisting of an acid of cetirizine, an acid of levocetirizine, an acid of loratadine, an acid of fexofenadine, an acid of rupatadine, an acid of acrivastine, an acid of ebastine, an acid of bilastine, and a combination of two or more thereof. The salt of the non-sedating antihistamine is selected from the group consisting of a salt of cetirizine, a salt of levocetirizine, a salt of loratadine, a salt of fexofenadine, a salt of rupatadine, a salt of acrivastine, a salt of ebastine, a salt of bilastine, and a combination of two or more thereof. The amide of a non-sedating antihistamine is selected from the group consisting of an amide of cetirizine, an amide of levocetirizine, an amide of loratadine, an amide of fexofenadine, an amide of rupatadine, an amide of acrivastine, an amide of ebastine, an amide of bilastine, and a combination of two or more thereof.
- In at least one embodiment, the composition includes 0.1 to 5.0 wt.-% of the antihistamine, 0.2-10.0 wt.-% creatine, 0.1-5.0 wt.-% creatinine, and at least 75 wt.-% of the emu oil product. In at least one embodiment, the composition includes 2.0 wt.-% of the antihistamine, 1.0 wt.-% creatine, 0.5 wt.-% creatinine, and at least 85 wt.-% of the emu oil product. In at least one embodiment, the composition further includes a preservative, and a neutral emulsifying agent. In at least one embodiment, the composition includes 0.1 to 1.0 wt.-% of preservative. In at least one embodiment, the composition includes 0.2 wt.-% of preservative. In at least one embodiment, the preservative is methylparaben, and the emulsifying agent is propylene glycol.
- In at least one embodiment, the antihistamine is selected from the group consisting of cetirizine, a physiologically acceptable acid of cetirizine, a salt of cetirizine, an amide of cetirizine, and a combination of two or more thereof. In at least one embodiment, the antihistamine is selected from the group consisting of levocetirizine, a physiologically acceptable acid of levocetirizine, a salt of levocetirizine, an amide of levocetirizine, and a combination of two or more thereof.
- According to one aspect of the present invention, a method of treating wounds and inflammatory conditions of the skin in mammals includes topically applying to the skin of a mammal a topically administrable composition that includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more thereof, a therapeutic amount of creatine, a therapeutic amount of creatinine, and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination thereof; and repeating the topical application of the composition as indicated for resolution or control of the skin wound.
- In at least one embodiment, the method includes a non-sedating antihistamine is selected from the group consisting of cetirizine, levocetirizine, loratadine, fexofenadine, rupatadine, acrivastine, ebastine, bilastine, and a combination of two or more thereof. In at least one embodiment, the method includes a physiologically acceptable acid of the non-sedating antihistamine is selected from the group consisting of an acid of cetirizine, an acid of levocetirizine, an acid of loratadine, an acid of fexofenadine, an acid of rupatadine, an acid of acrivastine, an acid of ebastine, an acid of bilastine, and a combination of two or more thereof. In at least one embodiment, the method includes a salt of the non-sedating antihistamine is selected from the group consisting of a salt of cetirizine, a salt of levocetirizine, a salt of loratadine, a salt of fexofenadine, a salt of rupatadine, a salt of acrivastine, a salt of ebastine, a salt of bilastine, and a combination of two or more thereof. In at least one embodiment, the method includes an amide of a non-sedating antihistamine is selected from the group consisting of an amide of cetirizine, an amide of levocetirizine, an amide of loratadine, an amide of fexofenadine, an amide of rupatadine, an amide of acrivastine, an amide of ebastine, an amide of bilastine, and a combination of two or more thereof.
- In at least one embodiment, the composition of the method includes 0.1 to 5.0 wt.-% of the antihistamine, 0.2-10.0 wt.-% creatine, 0.1-5.0 wt.-% creatinine, and at least 75 wt.-% of the emu oil product. In at least one embodiment, the composition of the method includes 2.0 wt.-% of the antihistamine, 1.0 wt.-% creatine, 0.5 wt.-% creatinine, and at least 85 wt.-% of the emu oil product. In at least one embodiment, the composition of the method includes an antihistamine selected from the group consisting of cetirizine, a physiologically acceptable acid of cetirizine, a salt of cetirizine, an amide of cetirizine, and a combination of two or more thereof. In at least one embodiment, the composition of the method includes an antihistamine selected from the group consisting of levocetirizine, a physiologically acceptable acid of levocetirizine, a salt of levocetirizine, an amide of levocetirizine, and a combination of two or more thereof.
-
FIG. 1 shows a method of treating wounds of the skin according to the present disclosure. - The present application discloses various formulations and methods for using the same for the treatment of wounds and inflammatory conditions of the skin in mammals. According to one aspect of the present disclosure, a formulation for the treatment and promotion of healing of wounds of the skin is disclosed. For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to various embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of this disclosure is thereby intended, such alterations, modifications, and further applications of the principles of the disclosure being contemplated as would normally occur to one skilled in the art to which the disclosure relates.
- A number of explanations and clinical trials are provided by way of explanation and not limitation. No theory of how the disclosure operates is to be considered limiting, whether proffered by virtue of description, comparison, or example. For the purposes of this disclosure, the term “emu oil” refers to lipid compositions, oils, and preparations of oils derived from the emu.
- Emu oil, extracted or rendered from the body fat of the emu bird, has a number of beneficial properties for the treatment of wounds and inflammatory conditions of the skin. The beneficial properties of emu oil include that emu oil is noncomedogenic, antibacterial, moisturizing, anti-inflammatory, emulsifying, enhances transdermal penetration, and has a low potential for skin irritation. Taking each of these beneficial properties in turn, emu oil is noncomedogenic, meaning emu oil will not clog skin pores. Other such oils tend to clog pores in skin, which can result in the development of acne. Such oils include synthetic oils, like mineral oils, or animal oils, like mink or lard. Moreover, emu oil has been demonstrated to be antibacterial and moisturizing to skin. Bacterial secondary colonization and infection play important roles in the pathogenesis of atopic dermatitis, and the antibacterial properties of emu oil address this contributing factor. Further, moisturizers by themselves are therapeutic agents in the treatment of patients with psoriasis, atopic dermatitis, and other forms of eczema because moisturizers can improve skin hydration and normalize keratinocyte differentiation.
- Emu oil has excellent skin barrier penetrating features and can enhance the transdermal penetration of active compounds, compounds otherwise unable to effectively treat disease beyond the epidermis. Emu oil is known to contain triglyceride esters of long-chain saturated and unsaturated fatty acids, including oleic acid, linoleic acid, palmitic acid, and stearic acid. Table 1 contains the typical chemical composition of emu oil which, being almost entirely triglyceride in nature, is a nearly completely neutral lipid. The transdermal penetration properties of emu oil are generally attributable to oleic acid, which enables penetration by fluidizing the intercellular lipids of the stratum corneum. However, studies of various long-chain fatty acids, including oleic acid, used as penetration enhancers have not reported a synergistic effect of using this particular property of emu oil with other active compounds as described herein.
- Two other valuable properties of emu oil for a topical treatment delivery system are its emulsifying properties and low potential for irritation. Such emulsifying properties, absent the potential for irritation, enable emu oil to serve as both a carrier and an active compound in a formulation. In addition to the beneficial properties mentioned above, emu oil has anti-inflammatory properties. For example, topically administered emu oil has been shown to be as effective as orally administered, high-dose ibuprofen. Research suggests that at least some of emu oil's anti-inflammatory properties are due to TNF-alpha inhibition, which is a key target inflammatory molecule in systemic psoriasis therapy. Examples of prescription treatments for systemic psoriasis that operate by inhibiting TNF-alpha include Enbrel® and Humira®. However, prior to the present disclosure, no topical formulation with TNF-alpha inhibitory effects has been used to treat inflammatory or any other disease of the skin. Therefore, emu oil may act as a therapeutic agent for some skin conditions independent of any other active compound.
- Certain of the beneficial properties of emu oil are most effective in treating specific types of skin conditions and less effective on others. Nonetheless, by combining emu oil with additional active compounds, the beneficial properties of emu oil may potentiate the therapeutic effects of both the emu oil and the additional active compounds. Accordingly, in at least one embodiment of the present disclosure, emu oil may be included in a formulation to dissolve one or more additional active compounds, carry the one or more additional active compounds through the skin barrier, and provide one or more therapeutic effects that are synergistically enhanced by the combination with the one or more additional active compounds.
- In at least one embodiment according to the present disclosure, emu oil may be combined with a non-sedating antihistamine compound to treat wounds and inflammatory conditions of the skin such as psoriasis and atopic dermatitis. One non-limiting example of a non-sedating antihistamine is cetirizine. Cetirizine is commonly used orally to treat hay fever, urticaria (i.e., hives), angioedema, and allergies. In addition to antiallergic, bronchodiliatory, and antispasmodic properties, cetirizine has numerous pharmacological effects that are highly useful for the treatment of wounds and inflammatory conditions of the skin if used as a topical agent.
- As a potent second-generation antihistamine, cetirizine has antipruritic properties that are very beneficial in treating wounds and inflammatory skin conditions, particularly atopic dermatitis, which has been described as a vicious cycle of itch-scratch-itch. In addition to relieving the symptoms of itch, antipruritic antihistamines help to prevent progression of the condition by suppressing the scratching impulse (i.e., the so-called Koebner phenomenon). Moreover, as a second-generation, non-sedating antihistamine, cetirizine has an excellent safety profile, which enables cetirizine (marketed as Zyrtec®) to be sold over-the-counter without a prescription. Further, cetirizine and its related isomers are unique among non-sedating antihistamines in that each has various anti-inflammatory properties useful for the treatment of inflammatory skin disease. Namely, cetirizine inhibits expression of adhesion molecules in patients with both atopic dermatitis and psoriasis and inhibits both T lymphocytes and monocytes, which play a central role in the pathogenesis of atopic dermatitis and psoriasis. Finally, cetirizine exerts anti-inflammatory effects on neutrophils apart from H1 antagonism and inhibits eosinophil-related skin inflammation.
- The anti-inflammatory properties of cetirizine are distinct from its other H1 antihistamine features. For example, diphenhydramine (marketed as Benadryl®) is specifically contraindicated to treat inflammatory skin disease, such as eczema and psoriasis. In fact, where sold in the United States, the packaging for diphenhydramine includes a warning label clearly stating that it should not be used on “raw or broken skin” or “areas producing discharge.” Other commonly used non-sedating antihistamines that do not have anti-inflammatory properties include loratadine (marketed as Claritin®) and fexofenadine (marketed as Allegra®). Therefore, not all non-sedating, H1 antihistamines are appropriate for the treatment of inflammatory skin conditions.
- Though emu oil and cetirizine both have anti-inflammatory properties, each utilizes completely different biochemical pathways. Consequently, instead of enabling merely additive beneficial anti-inflammatory effects, the combination of emu oil and cetirizine provides a synergistic enhancement of the beneficial effects of both active compounds in treating inflammatory skin conditions. Furthermore, emu oil, in addition to being a therapeutic agent, also enables penetration of cetirizine into the skin, thereby improving the efficacy of cetirizine separate from the synergistic effect.
- Cetirizine is a racemic 50/50 mixture of levocetirizine, which is the active enantiomer (or L-stereoisomer), and the much less biologically active enantiomer (or D-stereoisomer) Like cetirizine, levocetirizine is a non-sedating antihistamine that includes anti-inflammatory properties. Accordingly, in at least one embodiment of the present disclosure, emu oil may be combined with levocetirizine to treat wounds and inflammatory conditions of the skin such as psoriasis and atopic dermatitis. Other non-sedating, anti-inflammatory antihistamines include, but are not limited to rupatadine, acrivastine, ebastine and bilastine.
- Wound healing after any type of injury to the skin is an extremely complex, multistage process characterized by inflammation and new tissue formation and remodeling, which are both processes that require great amounts of cellular energy. Excessive inflammation and bacterial infection can delay wound healing and cause further scaring. Moreover, serious skin infections can become systemic and life threatening, for example, as with sepsis. Many wound healing creams, such as Neosporin® or Polysporin®, contain antibacterial medicines. However, dermatologists prescribe these wound healing creams infrequently because of high prevalence of contact dermatitis, or “poison ivy-type” allergic reactions, associated with the use of such treatments. Further, most healing wounds show signs of pruritus, and the resulting scratching can delay wound healing.
- In at least one embodiment of the present disclosure, emu oil may be combined with a mixture of creatine and creatinine, denoted as “Cr/Crt,” to treat and promote the healing of wounds of the skin, as well as inflammatory skin conditions such as psoriasis and atopic dermatitis. As disclosed herein, the application of Cr/Crt results in the regeneration of phosphocreatine molecules (“Pcr”) in mammalian skin. Because Pcr assists in regenerating ATP molecules, which produce energy in skin and other cells, topical application of Pcr via the application of Cr/Crt can provide skin cells with the energy needed to heal wounds. Further, the epidermal transport properties of emu oil facilitate penetration of Cr/Crt through the skin barrier, which is particularly effective in treating partially healed wounds.
- The combination of emu oil and Cr/Crt in one topical formulation enables these active compounds to synergistically aid the healing of wounds and inflammatory conditions of the skin. In addition to facilitating penetration of Cr/Crt through the skin barrier, emu oil also promotes wound healing by reducing excessive inflammation, which can interfere with wound healing and induce excessive scaring of a wound. Moreover, the antibacterial properties of emu oil promote wound healing by reducing the incidence of secondary infection, which can further interfere with the healing process. Previous studies have shown that emu oil alone can decrease wound healing time and decrease scar formation in burn victims based on the results of a double-blind study. Therefore, by combining emu oil and Cr/Crt in one treatment, the formulation may promote and facilitate the healing process of skin wounds by providing cellular energy to drive the healing process while concurrently reducing inflammation and the incidence of bacterial infection.
- In at least one embodiment of the present disclosure, emu oil may be combined with Cr/Crt and a non-sedating antihistamine to treat skin wounds and promote the healing process of skin wounds, as well as inflammatory skin conditions. As disclosed herein, non-sedating antihistamines, such as cetirizine, have anti-inflammatory and antipruritic properties that operate through different biochemical pathways from emu oil. These properties can be advantageous in promoting the healing process of skin wounds. Most healing skin wounds show signs of pruritus, and the resulting scratching can delay wound healing. Accordingly, the antipruritic properties of cetirizine are of value in the healing process. Further, the anti-inflammatory properties of certain non-sedating antihistamines, such as cetirizine, can promote wound healing by reducing excessive inflammation that can interfere with wound healing and induce excessive scaring of a wound. As disclosed herein, the combination of a non-sedating antihistamine, Cr/Crt, and emu oil has now been shown to synergistically potentiate the effects of these active compounds to accelerate the wound healing process. Consequently, a formulation combining emu oil, Cr/Crt, and a non-sedating antihistamine has been demonstrated to facilitate the wound healing process by addressing key aspects of the healing process via different biochemical pathways. The use of natural energy supplementation, for example with the topical use of Cr/Crt, in combination with anti-inflammatory compounds to facilitate the healing process in mammalian skin has not been disclosed previously.
- In at least one embodiment according to the present disclosure, a
formulation 10 may contain by weight 75-100% emu oil, 0.1-5.0% non-sedating antihistamine, a Cr/Crt mixture of 0.2-10.0% creatine and 0.1-5.0% creatinine, and 0.1-1.0% preservative, with the balance being a neutral emulsifying solvent. In at least one embodiment, theformulation 10 may contain by weight 75-100% emu oil, 0.1-5.0% cetirizine, a Cr/Crt mixture of 0.2-10.0% creatine and 0.1-5.0% creatinine, 0.1-1.0% methylparaben preservative, and the balance propylene glycol or other neutral emulsifying solvent. In at least one embodiment, theformulation 10 may contain by weight at least 85% emu oil, 2.0% cetirizine, a Cr/Crt mixture of 1% creatine and 0.5% creatinine, 0.2% methylparaben preservative, and the balance propylene glycol. In at least one embodiment, theformulation 10 may contain by weight 75-100% emu oil, 0.1-5.0% levocetirizine, a Cr/Crt mixture of 0.2-10.0% creatine and 0.1-5.0% creatinine, 0.1-1.0% methylparaben preservative, and the balance propylene glycol or other neutral emulsifying solvent. In at least one embodiment, theformulation 10 may contain by weight at least 85% emu oil, 2.0% levocetirizine, a Cr/Crt mixture of 1% creatine and 0.5% creatinine, 0.2% methylparaben preservative, and the balance propylene glycol. - In one aspect of the present disclosure, the formulations disclosed herein may be used in a
method 100 of treating wounds and inflammatory conditions of the skin as shown inFIG. 1 . Themethod 100 may include astep 110 of applying theformulation 10 to an affected area of skin. Themethod 100 may further include astep 120 of periodically repeating application of theformulation 10 to the affected area of skin until the wound is healed or the inflammatory condition is resolved or controlled. - The efficacy of combining emu oil with non-sedating antihistamine and with Cr/Crt was determined by the following experiment. The following experiment is illustrative, but not limiting, of the methods and compositions of the present disclosure. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and obvious to those skilled in the art, having the benefit of this disclosure, are within the scope of the present disclosure.
- In order to determine the efficacy of combining emu oil, a non-sedating antihistamine, and Cr/Crt as active compounds for the promotion of wound healing and the treatment of inflammatory skin conditions, a single-blind clinical study was conducted. The study was designed to determine: (i) the efficacy of the active compounds in promoting the healing process of skin wounds; (ii) whether the active compounds worked synergistically or simply provided additive effects; and (iii) the relative quantifiable effectiveness of each of the active compounds. Because of very stringent inclusion criteria, only five patients were enrolled and completed the study. As a single-blind study, the five research subjects received five tubes of preparations in cream form, labeled as A, B, C, D, and E, without knowledge of the formulations therein. However, a principal investigator and a study coordinator knew and recorded the formulations contained in each tube. Regarding the active compounds included in the study, Cream A included Cr/Crt and cetirizine in an emu oil base, Cream C included only emu oil, Cream D included Cr/Crt in an emu oil base, and Cream E included cetirizine in an emu oil base. Cream B, which contained no active compounds, included only propylene glycol base and served as a placebo. Cream B was used as a control preparation to provide a reference point for the degree of improvement observed for the other trial preparations. Each cream included an identical amount of Cr/Crt, namely 1.5% by weight, which included 1.0% creatine and 0.5% creatinine by weight. Further, each cream included methylparaben as a preservative and varying amounts of propylene glycol as a neutral emulsifying solvent. The study was conducted for 15 days.
- Subjects selected for the study had at least five different wounds on different areas of their body. The causes of the wounds included in the study included skin cancer treatment sites, shave or burn removal of warts, and skin biopsy sites. Accordingly, each research subject applied each of the trial creams to a different wound site on the subject's body selected at random by the subject. Each trail cream was applied on one wound only. Consequently, each research subject was his/her own positive and negative control. Further, though each wound was somewhat different and located in different anatomical areas from one another, the random selection of the treatment site by the subject for a given trial cream ensured statistical independence in the design of the study.
- At the end of the study, each research subject completed a questionnaire specifically asking “which of the five creams worked the best” and asking the subject to numerically rate the efficacy of each cream on a scale of 0 (not effective) to 10 (extremely effective). The subjects' ratings were then multiplied by a factor of ten to enable simple percentage point comparisons between the trial creams. Moreover, each subject was asked to report any systemic or dermatological side effects of the creams, such as irritation, stinging, or pruritus. The subjects were asked to rank the trial cream that produced the fastest healing with least side effects as a “10.” After the subjects ranked the cream that worked the best, each subject was told that cream B was a placebo and was asked to rate creams C, D, and E in comparison to cream B. Because scar tissue requires 6-12 months to completely form and because each wound was a different and in different anatomical area, the study could not include a determination of which cream produced best cosmetic results. Instead, the evaluations of the subjects' wounds addressed which trial cream produced the fastest healing with minimal subjective and objective side effects. Theoretically, the fastest acting treatment will translate into best cosmetic results.
- Furthermore, the clinical response of each subject was assessed by the principal investigator, a physician trained, experienced, and Board Certified in dermatology, at the end of the 15-day study by comparing the condition of the subjects' wounds to a pre-trial evaluation on 0 to 10 scale similar to that at used by the subjects, where “10” indicated the cream that produced the fastest healing with least side effects, “5” indicated that wound healing was 50% better than the placebo, and zero indicted that wound healing was no better than the placebo. The physician compared the rate of healing and subjective side effects, such as pain, itching and burning, of creams A, C, D, and E in comparison to the placebo, Cream B. Similarly, the physician's evaluations were then multiplied by a factor of ten to enable simple percentage point comparisons between the trial creams. Finally, the study coordinator obtained clinical photographs of all areas treated at the beginning and end of the study.
- The research subjects did not use any other prescription medication or over-the-counter topical preparation during the duration of the study. Informed written consent was obtained prior to initiation of the study from each research subject. No financial compensation was provided to any of the research subjects; however, each received a complimentary office visit and free medication. Further, at the end of the study, the subjects were offered and received a free complimentary tube of the cream of their choice (either cream A, B, C, D, or E).
- Table 2 presents the physician's evaluations of the improvement or worsening of the research subjects' skin conditions by the end of the study, relative to the beginning of the study and the control Cream B, for each of the trial creams A, C, D, and E. As shown Table 2, Cream A was rated most effective because it demonstrated the greatest improvement compared to creams B, C, D, and E, as reflected in the mean evaluation ratings across all subjects. Statistical analysis determined that the demonstrated improved effect of Cream A over the other creams was statistically significant (i.e., p<0.05). Further, Cream A had no reported side effects.
- Table 2 includes a column of data for the “Additive Effect of Creams C, D, and E” calculated for each subject based upon the physician's evaluation. The calculated additive effect of Cream C, Cream D, and Cream E was determined by, first, subtracting the rated effect of Cream B (the control) from the ratings given to Cream C, Cream D, and Cream E, which results in a value representing the beneficial effect of each cream in addition to the effect provided by Cream B. The resulting additional effects were then added together. Essentially, the calculated additive effect quantifies the combined effects of Cream C, Cream D, and Cream E, beyond the effect of the control cream, attributable to the active compounds operating separately. Thus, the calculated additive effect represents the expected or anticipated effect of combining and administering the three active compounds, Cr/Crt, cetirizine, and emu oil. On the other hand, the extent to which the rated effect of Cream A exceeds the calculated additive effect of Cream C, Cream D, and Cream E represents the unexpected and synergistic effect of combining and administering the three active compounds together. The synergistic effect may be calculated by subtracting the calculated additive effect of Cream C, Cream D, and Cream E from the rated evaluations for Cream A. Accordingly, Table 2 further includes the resulting unexpected and synergistic effect for each subject under column heading, “Synergistic Effect of Cream A,” which contains the calculated percentage point improvement of Cream A produced by the synergistic effect of Cream A beyond the simple additive effects of the active compounds administered separately via Cream C, Cream D, and Cream E.
- As shown in Table 2, Cream A was on average 50% more effective than the net effects of Cream C, Cream D, and Cream E taken separately. Further, the synergistic effect was statistically significant. Because the ratings given to Cream A were statistically greater than the calculated additive effect of Cream C, Cream D, and Cream E, one may conclude that the combined effect of the active compounds included in Cream A exceeded the expected effect of these compounds acting separately by 50% on average. Therefore, the study unequivocally demonstrated that Cr/Crt, cetirizine, and emu oil synergistically potentiate each other's beneficial effects and that the synergistic effect was statistically significant.
- The data of Table 2 further demonstrates that, while treatment with emu oil alone (Cream C) produced some benefits, the combination of Cr/Crt and emu oil (Cream D) has statistically significant beneficial effects for wound healing. One reason for including a placebo without an active compound in the study was to distinguish whether an active compound, and in particular Cr/Crt, might have a negative impact on wound healing. To the contrary, as the results for Cream D indicate, Cr/Crt combined with emu oil demonstrated a statistically significant improvement in wound healing.
- Table 3 presents the research subjects' ratings of their own skin conditions at the end of the study, relative to the beginning of the study, for each of the trial creams A, B, C, and D. As shown in Table 3, the subjects' ratings generally corroborated the physician's evaluations. For example, most of the research subjects rated Cream A as the most effective for the treatment of his/her wound to a statistically significant degree. One subject rated Cream D (Cr/Crt and emu oil) as most effective. Unlike Cream A, which demonstrated statistically significant improvement in comparison to the placebo (Cream B), creams C, D, and E did not achieve statistically significant improvement in comparison to Cream B.
- As shown in Table 3, Cream A was demonstrated to be 88% more effective than Cream B (the control) to a statistically significant degree as rated by the research subjects. In addition, Cream A was on average 24% more effective than the net effects of Cream C, Cream D, and Cream E taken separately, thereby demonstrating the same synergistic effect proven with the physician's evaluations, but as rated by the subjects. However, due to the small sample size, the synergistic effect based on the subjects' ratings was highly suggestive but not statistically significant (i.e., 0.10>p>0.05). In addition, the subjects' ratings similarly corroborated the physician's evaluations indicating a statistically significant improvement in wound healing using Cr/Crt in combination with emu oil. None of the research subjects reported any systemic side effects from any of the creams A, B, C, D, or E.
- In summary, the clinical study as a whole clearly demonstrated that cetirizine, emu oil, and Cr/Crt synergistically potentiated each other's beneficial effects to promote the healing process for wounds of the skin and other inflammatory skin conditions utilizing completely different biochemical pathways.
- While various embodiments of a formulation for the treatment of wounds and inflammatory skin conditions of the skin and methods for using the same have been described in considerable detail herein, the embodiments are merely offered by way of non-limiting examples of the disclosure described herein. It will therefore be understood that various changes and modifications may be made, and equivalents may be substituted for elements thereof, without departing from the scope of the disclosure. Indeed, this disclosure is not intended to be exhaustive or to limit the scope of the disclosure.
- Further, in describing representative embodiments, the disclosure may have presented a method and/or process as a particular sequence of steps. However, to the extent that the method or process does not rely on the particular order of steps set forth herein, the method or process should not be limited to the particular sequence of steps described. Other sequences of steps may be possible and are therefore contemplated by the inventor. Therefore, the particular order of the steps disclosed herein should not be construed as limitations of the present disclosure. In addition, disclosure directed to a method and/or process should not be limited to the performance of their steps in the order written. Such sequences may be varied and still remain within the scope of the present disclosure.
-
TABLE 1 Typical Emu Oil Fatty Acid Composition Fatty Acid Percentage by Weight Myristic 0.4% Palmitic 21.5% Palmitoleic 3.7% Stearic 10.6% Oleic 51.4% Linoleic 12.7% Linolenic 0.9% -
TABLE 2 Physician Evaluations of Trial Creams Ad- Syner- ditive gistic Effect Effect of of Creams Cream Sub- Cream Cream B Cream Cream Cream C, D A ject A (Control) C D E and E (%) 1 100 — 10 20 0 30 70 2 100 — 10 30 10 50 50 3 100 — 10 30 30 70 30 4 100 — 10 20 30 50 50 5 100 — 10 20 10 50 50 Mean 100 — 10 24 16 50 50 -
TABLE 3 Patient Ratings of Trial Creams Ad- Syner- ditive gistic Effect Effect of of Creams Cream Sub- Cream Cream B Cream Cream Cream C, D A ject A (Control) C D E and E (%) 1 100 — 20 20 10 50 50 2 40 — 20 100 0 120 −80 3 100 — 10 30 20 50 50 4 100 — 10 20 30 60 40 5 100 — 20 20 0 40 60 Mean 88 — 16 38 12 64 24
Claims (20)
1. A composition, comprising:
a quantity of a non-sedating antihistamine;
a quantity of creatine;
a quantity of creatinine; and
a quantity of an emu oil product.
2. The composition of claim 1 , wherein:
the quantity of the non-sedating antihistamine comprises 0.1-5.0% by weight;
the quantity of the creatine comprises 0.2-10.0% by weight;
the quantity of the creatinine comprises 0.1-5.0% by weight; and
the quantity of the emu oil product is at least 75% by weight.
3. The composition of claim 1 , wherein:
the quantity of the non-sedating antihistamine comprises 0.1-5.0% by weight;
the quantity of the creatine comprises 0.2-10.0% by weight;
the quantity of the creatinine comprises 0.1-5.0% by weight; and
the quantity of the emu oil product is at least 85% by weight.
4. The composition of claim 1 , wherein:
the quantity of the non-sedating antihistamine comprises 1.0-3.0% by weight;
the quantity of the creatine comprises 0.2-10.0% by weight;
the quantity of the creatinine comprises 0.1-5.0% by weight; and
the quantity of the emu oil product is at least 75% by weight.
5. The composition of claim 1 , wherein the non-sedating antihistamine comprises cetirizine.
6. The composition of claim 5 , wherein:
the quantity of the cetirizine comprises 0.1-5.0% by weight;
the quantity of the creatine comprises 0.2-10.0% by weight;
the quantity of the creatinine comprises 0.1-5.0% by weight; and
the quantity of the emu oil product is at least 75% by weight.
7. The composition of claim 5 , wherein:
the quantity of the cetirizine comprises 0.1-5.0% by weight;
the quantity of the creatine comprises 0.2-10.0% by weight;
the quantity of the creatinine comprises 0.1-5.0% by weight; and
the quantity of the emu oil product is at least 85% by weight.
8. The composition of claim 5 , wherein:
the quantity of the cetirizine comprises 1.0-3.0% by weight;
the quantity of the creatine comprises 0.2-10.0% by weight;
the quantity of the creatinine comprises 0.1-5.0% by weight; and
the quantity of the emu oil product is at least 75% by weight.
9. The composition of claim 5 , wherein:
the quantity of the cetirizine comprises 1.0-3.0% by weight; and
the quantity of the creatine and the quantity of the creatinine comprises 1.0-2.0% by weight in combination.
10. The composition of claim 1 , wherein the non-sedating antihistamine comprises levocetirizine.
11. The composition of claim 10 , wherein:
the quantity of the levocetirizine comprises 0.1-5.0% by weight;
the quantity of the creatine comprises 0.2-10.0% by weight;
the quantity of the creatinine comprises 0.1-5.0% by weight; and
the quantity of the emu oil product is at least 75% by weight.
12. The composition of claim 10 , wherein:
the quantity of the levocetirizine comprises 0.1-5.0% by weight;
the quantity of the creatine comprises 0.2-10.0% by weight;
the quantity of the creatinine comprises 0.1-5.0% by weight; and
the quantity of the emu oil product is at least 85% by weight.
13. The composition of claim 10 , wherein:
the quantity of the levocetirizine comprises 1.0-3.0% by weight;
the quantity of the creatine comprises 0.2-10.0% by weight;
the quantity of the creatinine comprises 0.1-5.0% by weight; and
the quantity of the emu oil product is at least 75% by weight.
14. The composition of claim 10 , wherein:
the quantity of the cetirizine comprises 1.0-3.0% by weight; and
the quantity of the creatine and the quantity of the creatinine comprises 1.0-2.0% by weight in combination.
15. A composition, comprising:
a quantity of a non-sedating antihistamine or an acid, salt, or amide thereof;
a quantity of a mixture comprising creatine and creatinine; and
a quantity of an emu oil product;
wherein the quantity of the mixture comprising creatine and creatinine is 0.2-10% by weight.
16. The composition of claim 15 , wherein:
the non-sedating antihistamine comprises cetirizine or levocetirizine; and
wherein the quantity of the mixture comprising creatine and creatinine is 1.0-2.0% by weight.
17. The composition of claim 16 , wherein:
the quantity of the non-sedating antihistamine comprises 1.0-3.0% by weight; and
the quantity of the emu oil product is at least 75% by weight.
18. The composition of claim 17 , further comprising:
a quantity of a preservative.
19. A composition, comprising:
a quantity of cetirizine or levocetirizine;
a quantity of a mixture comprising creatine and creatinine; and
a quantity of an emu oil product of at least 75% by weight.
20. The composition of claim 19 , wherein:
the quantity of the mixture comprising creatine and creatinine is 1.0-2.0% by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/431,107 US20170151289A1 (en) | 2012-04-16 | 2017-02-13 | Formulations and methods for treatment of wounds and inflammatory skin conditions |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261624725P | 2012-04-16 | 2012-04-16 | |
US201261725761P | 2012-11-13 | 2012-11-13 | |
PCT/US2013/032728 WO2013158319A1 (en) | 2012-04-16 | 2013-03-17 | Formulations and methods for treatment of wounds and inflammatory skin conditions |
US201414394641A | 2014-10-15 | 2014-10-15 | |
US15/431,107 US20170151289A1 (en) | 2012-04-16 | 2017-02-13 | Formulations and methods for treatment of wounds and inflammatory skin conditions |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/394,641 Continuation US9566306B2 (en) | 2012-04-16 | 2013-03-17 | Formulations and methods for treatment of wounds and inflammatory skin conditions |
PCT/US2013/032728 Continuation WO2013158319A1 (en) | 2012-04-16 | 2013-03-17 | Formulations and methods for treatment of wounds and inflammatory skin conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170151289A1 true US20170151289A1 (en) | 2017-06-01 |
Family
ID=49383943
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/394,725 Active 2035-11-25 US11224619B2 (en) | 2012-04-16 | 2013-03-17 | Formulations and methods for treatment of inflammatory skin diseases |
US14/394,705 Active 2035-10-27 US11224618B2 (en) | 2012-04-16 | 2013-03-17 | Formulations and methods for treatment of acne and inflammatory skin conditions |
US14/394,641 Active US9566306B2 (en) | 2012-04-16 | 2013-03-17 | Formulations and methods for treatment of wounds and inflammatory skin conditions |
US15/431,107 Abandoned US20170151289A1 (en) | 2012-04-16 | 2017-02-13 | Formulations and methods for treatment of wounds and inflammatory skin conditions |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/394,725 Active 2035-11-25 US11224619B2 (en) | 2012-04-16 | 2013-03-17 | Formulations and methods for treatment of inflammatory skin diseases |
US14/394,705 Active 2035-10-27 US11224618B2 (en) | 2012-04-16 | 2013-03-17 | Formulations and methods for treatment of acne and inflammatory skin conditions |
US14/394,641 Active US9566306B2 (en) | 2012-04-16 | 2013-03-17 | Formulations and methods for treatment of wounds and inflammatory skin conditions |
Country Status (3)
Country | Link |
---|---|
US (4) | US11224619B2 (en) |
EP (3) | EP2838521A4 (en) |
WO (3) | WO2013158317A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784462A (en) * | 2014-02-25 | 2014-05-14 | 宋俊智 | Pharmaceutical preparation containing bilastine and steroids |
US9993452B2 (en) | 2014-12-05 | 2018-06-12 | Vireo Systems, Inc. | Compositions and methods for treatment of inflammation |
TWI825013B (en) * | 2017-04-19 | 2023-12-11 | 日商帝國製藥股份有限公司 | Patches containing rupatadine |
IL295102A (en) | 2020-02-28 | 2022-09-01 | Joyce H Ma | Formulations and uses thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4772591A (en) * | 1985-09-25 | 1988-09-20 | Peritain, Ltd. | Method for accelerated wound healing |
WO1992008470A1 (en) | 1990-11-14 | 1992-05-29 | Emu Products Western Australia Pty. Ltd. | Anti-inflammatory composition derived from emu oil |
GB9305282D0 (en) | 1993-03-15 | 1993-05-05 | Ucb Sa | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine |
US6103246A (en) * | 1993-06-03 | 2000-08-15 | Tisdale; Carrie J. | Creams and lotions containing emu oil |
US5472713A (en) | 1994-11-23 | 1995-12-05 | Elf Resources, Inc. | Therapeutic uses of emu oil |
US5744128A (en) | 1995-05-03 | 1998-04-28 | Holick; Michael F. | Use of emu oil for stimulating skin and hair growth |
BR9711019A (en) | 1996-08-02 | 1999-08-17 | Plum Kemi Prod | Oil-in-water emulsion for use on human skin for cleaning, preserving or improving the condition of the skin |
WO1998033474A1 (en) * | 1997-01-31 | 1998-08-06 | Kenneth Hoyt | Use of oil from emu or rhea birds as trans-membrane carriers for delivery of drugs, peptides and vaccines |
US7220427B2 (en) | 1998-07-08 | 2007-05-22 | Oryxe | Mixture for transdermal delivery of low and high molecular weight compounds |
ES2221624T3 (en) | 1999-08-26 | 2005-01-01 | Ganeden Biotech, Inc. | USE OF EMU OIL AS A VEHICLE FOR ANTIFUNGIC, ANTIBACTERIAL AND ANTIVIRIC MEDIATIONS. |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
WO2001087236A2 (en) | 2000-05-17 | 2001-11-22 | Klein Gerald L | Topical administration of pharmacological compositions for non-systemic treatment of pruritus |
US20030212078A1 (en) | 2001-05-17 | 2003-11-13 | Klein Gerald L. | Topical administration of pharmacological compositions for non-systemic treatment of pruritus |
DE10136077A1 (en) * | 2001-07-25 | 2003-02-13 | Beiersdorf Ag | Cosmetic or dermatological preparations containing creatinine and creatine, useful e.g. for combating skin aging symptoms or treating inflammatory conditions such as eczema or psoriasis |
US6806213B2 (en) * | 2001-12-20 | 2004-10-19 | Kimberly-Clark Worldwide, Inc. | Disposable wash cloth and method of using |
JP2003212773A (en) * | 2002-01-04 | 2003-07-30 | Oramon Arzneimittel Gmbh | Topical medicine composition of cetirizine and loratadine |
US6667026B1 (en) | 2002-03-15 | 2003-12-23 | Pocono Falls, Inc. | Allergic contact dermatitis treatment and composition therefor |
US20040185115A1 (en) | 2002-05-17 | 2004-09-23 | Maurine Pearson | Emu oil based methods and compositions for skin ailments |
US20040132743A1 (en) | 2002-06-21 | 2004-07-08 | Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories, Inc. | Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20040198743A1 (en) | 2003-01-31 | 2004-10-07 | Schering Corporation | Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists |
CA2516621C (en) | 2003-02-28 | 2010-01-12 | E-L Management Corp. | Method for increasing hair growth using a creatine compound |
US20040266787A1 (en) | 2003-03-25 | 2004-12-30 | Dr. Reddy's Laboratories Limited | Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof |
DE10349665A1 (en) | 2003-10-24 | 2005-06-09 | Beiersdorf Ag | Insect repellent textile |
US9248146B2 (en) | 2003-10-24 | 2016-02-02 | Adhesives Research, Inc. | Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents |
CA2556503A1 (en) | 2004-02-19 | 2005-09-01 | Occell Inc. | Topical formulations for the treatment of skin conditions |
US20050238597A1 (en) | 2004-04-26 | 2005-10-27 | Mccook John P | Topical treatment of acne, seborrheic dermatitis, and oily skin with formulations containing histamine antagonists |
US20060058387A1 (en) * | 2004-09-15 | 2006-03-16 | Albert Aebi | Composition and method for treating skin conditions |
US20070009607A1 (en) | 2005-07-11 | 2007-01-11 | George Jones | Antibacterial/anti-infalmmatory composition and method |
US20130115202A1 (en) | 2005-08-31 | 2013-05-09 | Theta Biomedical Consulting & Development Co., Inc | Anti-inflammatory compositions for treating neuro-inflammation |
EP1945307B1 (en) | 2005-10-11 | 2013-03-27 | DPT Laboratories, LTD. | Surfactant-free dispersions, compositions, and use in topical formulations |
GB0524962D0 (en) | 2005-12-07 | 2006-01-18 | Pharmakodex Ltd | Topical pharmaceutical compositions |
JP2009528382A (en) | 2006-03-01 | 2009-08-06 | トリストラータ・インコーポレイテッド | Compositions and methods for topical treatment of tar-responsive skin diseases |
CA2645073A1 (en) | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
US20080031833A1 (en) * | 2006-03-13 | 2008-02-07 | Oblong John E | Combined energy and topical composition application for regulating the condition of mammalian skin |
US20110104159A1 (en) | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
WO2008052198A2 (en) | 2006-10-26 | 2008-05-02 | Reliant Technologies, Inc. | Methods of increasing skin permeability by treatment with electromagnetic radiation |
MX2009004620A (en) | 2006-11-01 | 2009-05-15 | Veterinary Encapsulation Biosc | Delivery system for remote treatment of an animal. |
US20080255103A1 (en) * | 2007-04-12 | 2008-10-16 | Ballay Pharmaceuticals, Inc. | Antihistamine and anti-nausea pharmaceutical compositions for topical application |
EP2164481A2 (en) * | 2007-06-08 | 2010-03-24 | Bayer Consumer Care AG | Medicament comprising an active substance combination containing pantothenic acid or the derivatives thereof for the treatment of allergy symptoms |
US8623335B2 (en) | 2007-09-10 | 2014-01-07 | Tauna Ann Waddington | Scar and rosacea and other skin care treatment composition and method |
US20100008868A1 (en) | 2007-11-27 | 2010-01-14 | Harry Dugger | Sustained remission of atopic dermatitis |
WO2009089234A2 (en) | 2008-01-07 | 2009-07-16 | Auspex Pharmaceuticals | Substituted dibenzhydrylpiperazines |
KR20100005538A (en) * | 2008-07-07 | 2010-01-15 | 민경호 | Composition for treating skin injury |
US20100055161A1 (en) | 2008-08-27 | 2010-03-04 | Dong June Ahn | Hydrogel face mask for delivering skin care agents |
EP2323844A1 (en) | 2008-09-10 | 2011-05-25 | Silipos Inc. | Gelatinous elastomer compositions |
PL2400951T3 (en) | 2009-02-25 | 2019-02-28 | Mayne Pharma Llc | Topical foam composition |
DE102009013469B4 (en) | 2009-03-19 | 2014-04-17 | Bubbles And Beyond Gmbh | Preparation for external use |
GB0907019D0 (en) | 2009-04-24 | 2009-06-03 | Oxford Nutrascience Ltd | Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients |
US9327105B2 (en) | 2010-03-26 | 2016-05-03 | Itrace Biomedical Inc. | Active transdermal drug delivery system and the method thereof |
US20120027876A1 (en) | 2010-07-27 | 2012-02-02 | Sara Beth Ford | Composition and Method for the Topical Treatment of Dermatitis |
US20120100183A1 (en) * | 2010-10-23 | 2012-04-26 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
US8858970B2 (en) | 2011-01-13 | 2014-10-14 | Austin Research Labs Corp. | High load dispersions |
US9138446B2 (en) * | 2011-06-08 | 2015-09-22 | Scott Alan Weisenfluh | EMU oil in combination with other active ingredients for treating skin imperfections |
-
2013
- 2013-03-17 US US14/394,725 patent/US11224619B2/en active Active
- 2013-03-17 WO PCT/US2013/032726 patent/WO2013158317A1/en active Application Filing
- 2013-03-17 WO PCT/US2013/032728 patent/WO2013158319A1/en active Application Filing
- 2013-03-17 EP EP13777761.1A patent/EP2838521A4/en not_active Withdrawn
- 2013-03-17 US US14/394,705 patent/US11224618B2/en active Active
- 2013-03-17 WO PCT/US2013/032727 patent/WO2013158318A1/en active Application Filing
- 2013-03-17 US US14/394,641 patent/US9566306B2/en active Active
- 2013-03-17 EP EP13778264.5A patent/EP2838509A4/en not_active Withdrawn
- 2013-03-17 EP EP13777719.9A patent/EP2838508A4/en not_active Withdrawn
-
2017
- 2017-02-13 US US15/431,107 patent/US20170151289A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2838521A1 (en) | 2015-02-25 |
EP2838508A1 (en) | 2015-02-25 |
US11224619B2 (en) | 2022-01-18 |
US20150093445A1 (en) | 2015-04-02 |
WO2013158317A1 (en) | 2013-10-24 |
EP2838508A4 (en) | 2015-03-11 |
US9566306B2 (en) | 2017-02-14 |
WO2013158319A1 (en) | 2013-10-24 |
US11224618B2 (en) | 2022-01-18 |
EP2838509A1 (en) | 2015-02-25 |
EP2838509A4 (en) | 2015-03-11 |
WO2013158318A1 (en) | 2013-10-24 |
US20150086644A1 (en) | 2015-03-26 |
EP2838521A4 (en) | 2015-03-11 |
US20150072996A1 (en) | 2015-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170151289A1 (en) | Formulations and methods for treatment of wounds and inflammatory skin conditions | |
AU2012254214B2 (en) | A topical formulation for treatment of hyperkeratotic skin | |
AU2012254214A1 (en) | A topical formulation for treatment of hyperkeratotic skin | |
IL266448B1 (en) | Topical detomidine formulations | |
US9034351B2 (en) | Compositions and methods for the treatment of skin diseases | |
PL190023B1 (en) | Application of a mixture of diole and alpha-hydroxyacid in treating | |
US11590211B2 (en) | Systems for treating dermal inflammatory conditions | |
WO2020222188A1 (en) | Methods of treating pruritus | |
EP3675814A1 (en) | Composition for topical treatment of non-microorganism-caused inflammatory skin and mucous-membrane diseases | |
KR20080097420A (en) | Topical preparation composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases | |
AU2004262934A1 (en) | Topical composition comprising terbinafine and hydrocortisone | |
US20100168254A1 (en) | Hydrogel composition for the treatment of dermatological disorders | |
EP1633374A1 (en) | Composition consisting of alkane dicarboxylic acids and a pharmaceutically active ingredient | |
JP2024509383A (en) | Topical formulations of JAK1/3 inhibitors and methods of use thereof for the treatment of atopic dermatitis and other skin conditions | |
WO2013173881A1 (en) | A dermatological composition | |
US20070141089A1 (en) | Topical composition comprising terbinaf ine adn hydrocortisone | |
JP2019501221A (en) | Formulations, manufacturing methods and uses for the treatment of extracellular matrix components of peripheral joints, spinal joints and / or connective tissues | |
BR102012015283A2 (en) | PHARMACOLOGICAL COMPOUND FOR TREATMENT AND REMISSION OF PSORIASIS OR SKIN INJURY AND ITS OBTAINING PROCESS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ZEMTSOV ENTERPRISES, LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZEMTSOV, ALEXANDER;REEL/FRAME:041240/0631 Effective date: 20151209 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |